Supernus Pharmaceuticals, Inc.

SUPN · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders4.3%

Institutions106.6%

Public / Other

	You	Peer avg
Revenue Growth	+32.4%	+73.3%
ROE	-10.5%	-118.2%

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$718.95M	$661.82M	$667.24M	$579.77M	$520.40M	$392.75M	$408.90M	$302.24M	$215.00M	$144.43M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$74.56M	$77.91M	–	–	$52.46M	$16.66M	$15.36M	$15.21M	$11.99M	$8.42M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$62.28M	$81.67M	$46.12M	$86.03M	$173.70M	$148.57M	$144.44M	$99.54M	$54.22M	$17.66M
Operating income as a percentage of revenue.	-8.7%	12.3%	6.9%	14.8%	33.4%	37.8%	35.3%	32.9%	25.2%	12.2%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$38.55M	$73.86M	$60.71M	$53.42M	$126.95M	$113.06M	$110.99M	$57.28M	$91.22M	$14.02M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.68	$1.34	$1.13	$1.01	$2.41	$2.16	$2.13	$1.00	$1.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.68	$1.32	$1.04	$0.98	$2.36	$2.10	$2.05	$1.00	$1.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$128.45M	$69.33M	$93.12M	$203.43M	$288.64M	$181.38M	$192.25M	$100.30M	$66.40M	$34.15M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.45B	$1.37B	$1.70B	$1.69B	$1.50B	$1.16B	$977.81M	$424.46M	$309.57M	$188.73M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$401.97M	–	–	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$390.93M	$332.34M	$816.30M	$873.30M	$759.24M	$564.85M	$524.79M	$156.98M	$117.81M	$69.86M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.06B	$1.04B	$886.20M	$815.85M	$744.86M	$595.43M	$453.02M	$267.48M	$191.75M	$118.88M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$47.33M	$171.95M	$116.83M	$127.13M	$138.40M	$143.13M	$128.99M	$114.64M	$66.81M	$32.12M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.34M	$725000	$412000	$2.04M	$3.45M	$2.74M	$844000	$2.03M	$1.60M	$2.10M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$45.99M	$171.23M	$116.41M	$125.08M	$134.95M	$140.39M	$128.14M	$112.61M	$65.21M	$30.02M

Supernus Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison

Income Statement

Balance Sheet

Cash Flow Statement